P Rougier

5.2k citations
70 papers · 3.9k indexed · 1 hit paper · h-index 16

Impact in

  • Hepatology top 0.5%
    • Hepatocellular Carcinoma Treatment and Prognosis
  • Oncology top 0.5%
    • Colorectal Cancer Treatments and Studies
    • Cancer Treatment and Pharmacology
    • Colorectal Cancer Surgical Treatments

Papers in

    • Hepatocellular Carcinoma Treatment and Prognosis 21
    • Colorectal Cancer Treatments and Studies 30
    • Cancer Treatment and Pharmacology 10
    • Colorectal Cancer Surgical Treatments 9

P Rougier

63 papers receiving 3.7k citations

Hit Papers

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial 2000 · 2.5k citations
2.5k200020262008201750010001.5k2.0k2.5k

Peers

P Rougier
Comparison fields: 5 of 93
  • Hepatology 1.2k
  • Oncology 3.1k
  • Pulmonary and Respiratory Medicine 1.2k
  • Pathology and Forensic Medicine 486
  • Gastroenterology 129
Replace Lucile Awad with:
Lucile Awad France
J. Wils Netherlands
M. Homerin France
D. Papamichael United Kingdom
Gérard Lledo France
N Le Bail France
J. Załuski Poland
Michelle R. Mahoney United States
Sergio Ricci Italy
Philip R. Clingan Australia
P Rougier relative to Lucile Awad France Lucile Awad's profile →
Citations per field
00.5×1.5×
Lucile Awad · 1×
Citations per year

Countries citing papers authored by P Rougier

Since Specialization
Citations

This map shows the geographic impact of P Rougier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P Rougier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P Rougier more than expected).

Fields of papers citing papers by P Rougier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P Rougier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P Rougier. The network helps show where P Rougier may publish in the future.

Co-authors

The 25 scholars most cited alongside P Rougier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with P Rougier Line = papers co-authored together P Rougier links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20174
2 20139
3
Utilizing Predictive Biomarkers to Improve Treatment Outcomes in Patients with Metastatic Colorectal Cancer (Mcrc): Results with Cetuximab Plus Folfiri in the Crystal Trial
20090
4
The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri
200811
5
Prise en charge thérapeutique des métastases hépatiques des cancers colo-rectaux
20082
6
Survival after peri-operative chemotherapy with folfox 4 and surgery for resectable colorectal cancer liver metastases. Final results of the eortc intergroup randomized phase III study 40983
20071
7
Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC)
200517
8 2005262
9 2004190
10 20041
11 200245
12 199810
13 19972
14
[Major hepatectomy after intra-arterial chemotherapy for initially unresectable liver tumors. Frequency, technical problems, results and indications].
19964
15 199440
16 199312
17
[Fibrinolytic treatment with urokinase and streptokinase for recurrent thrombosis in two valve prostheses for the aortic and mitral valves during pregnancy].
199114
18
[Anatomo-pathologic study of hepatic toxicity in intra-arterial hepatic chemotherapy].
198910
19
[Early adjuvant intraportal chemotherapy after hepatectomy for metastases of colorectal origin].
19860
20
Chimiothérapie des cancers médullaires de la thyroïde. Essais phase II avec adriamycine et cis-platinum administrés en monochimiothérapie.
19840

About P Rougier

P Rougier is a scholar working on Hepatology, Oncology, Pulmonary and Respiratory Medicine, Surgery and Epidemiology, having authored 70 papers that have together received 3.9k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (30 papers), Hepatocellular Carcinoma Treatment and Prognosis (21 papers), Multiple and Secondary Primary Cancers (11 papers), Cancer Treatment and Pharmacology (10 papers), Lung Cancer Treatments and Mutations (10 papers), Colorectal and Anal Carcinomas (9 papers), Colorectal Cancer Surgical Treatments (9 papers) and Gastric Cancer Management and Outcomes (9 papers). The work is most often cited by research in Hepatology (1.2k citations), Oncology (3.1k citations), Pulmonary and Respiratory Medicine (1.2k citations), Pathology and Forensic Medicine (486 citations) and Gastroenterology (129 citations). P Rougier has collaborated with scholars based in France, Germany and United Kingdom. Frequent co-authors include David Cunningham, Petr Karásek, Lucile Awad, AD Roth, May Alakl, J-Y Douillard, Timothy Iveson, Matilde Navarro, P Jandı́k and G. Gruia. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Annals of Oncology, Hepatology and CardioVascular and Interventional Radiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026